

Technology appraisal (TA) Titles are hyperlinks to full guidance	Date of TA Release <small>(N.B. if exact date is not specified in NICE documentation, the last day of the month published will be employed)</small>	Adherence of local formulary to NICE				
		Yes <small>(mark 'x' if applicable)</small>	N/A <small>(mark 'x' if applicable)</small>	Date of local decision <small>(DD/MM/YY)</small>	Time to implement <small>(days)</small>	Notes <small>(e.g. Additional stipulations, rationale, method of making available)</small>
2018-19						
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years [TA554]	21/12/2018	X		15/01/2019	25	
Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence [TA553]	19/12/2018	X		15/01/2019	27	
Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia [TA552]	19/12/2018	X		15/01/2019	27	
Lenvatinib for untreated advanced hepatocellular carcinoma [TA551]	19/12/2018	X		15/01/2019	27	
Vandetanib for treating medullary thyroid cancer [TA550]	12/12/2018	X		12/12/2018	0	Not recommend for use by NICE
Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal) [TA549]	05/12/2018		X	05/12/2018	0	
Decitabine for untreated acute myeloid leukaemia (terminated appraisal) [TA548]	05/12/2018		X	05/12/2018	0	
Tofacitinib for moderately to severely active ulcerative colitis [TA547]	28/11/2018	X		20/12/2018	22	
Padeliporfin for untreated localised prostate cancer [TA546]	21/11/2019	X		21/11/2018	0	Not recommend for use by NICE
Gemtuzumab ozogamicin for untreated acute myeloid leukaemia [TA545]	14/11/2018	X		15/01/2019	62	
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma [TA544]	17/10/2018	X		15/01/2019	90	
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs [TA543]	03/10/2018	X		18/10/2018	15	
Cabozantinib for untreated advanced renal cell carcinoma [TA542]	03/10/2018	X		16/10/2018	13	
Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia [TA541]	19/09/2018	X		16/10/2018	27	
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma [TA540]	03/09/2018	X		16/10/2018	43	
Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours [TA539]	29/08/2018	X		16/10/2018	48	
Dinutuximab beta for treating neuroblastoma [TA538]	22/08/2018		X	22/08/2018	0	No providers in SE London commissioned for this service
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs [TA537]	08/08/2018	X		16/08/2018	8	

Alectinib for untreated ALK-positive advanced non-small-cell lung cancer [TA536]	08/08/2018	X		04/09/2018	27	
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine [TA535]	08/08/2018	X		04/09/2018	27	
Dupilumab for treating moderate to severe atopic dermatitis [TA534]	01/08/2018	X		16/08/2018	15	
Ocrelizumab for treating relapsing–remitting multiple sclerosis [TA533]	25/07/2018	X		04/09/2018	41	
Ceneqermin for treating neurotrophic keratitis [TA532]	18/07/2018	X		18/07/2018	0	Not recommend for use by NICE
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [TA531]	18/07/2018	X		04/09/2018	48	
Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy [TA530]	04/07/2018	X		17/07/2018	13	
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer [TA529]	04/07/2018	X		17/07/2018	13	
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer [TA528]	04/07/2018	X		17/07/2018	13	
Beta interferons and glatiramer acetate for treating multiple sclerosis [TA527]	27/06/2018	X		17/07/2018	20	
Arsenic trioxide for treating acute promyelocytic leukaemia [TA526]	13/06/2018	X		17/07/2018	34	
Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy [TA525]	13/06/2018	X		17/07/2018	34	
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma [TA524]	13/06/2018	X		17/07/2018	34	
Midostaurin for untreated acute myeloid leukaemia [TA523]	13/06/2018	X		17/07/2018	34	
Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable [TA522]	13/06/2018	X		17/07/2018	34	
Guselkumab for treating moderate to severe plaque psoriasis [TA521]	13/06/2018	X		21/06/2018	8	
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy [TA520]	16/05/2018	X		17/07/2018	62	
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy [TA519]	25/04/2018	X		17/07/2018	83	
Tocilizumab for treating giant cell arteritis [TA518]	18/04/2018	X		17/07/2018	90	
Avelumab for treating metastatic Merkel cell carcinoma [TA517]	11/04/2018	X		17/07/2018	97	
		% "Yes"	% "N/A"	-	Average implement time (days)	

Adherence statistics for 2018-19		92.0%	8.0%		31	
----------------------------------	--	-------	------	--	----	--